Table 1.
Characteristics | Number (percent) |
---|---|
Baseline age in year (n = 1196) | |
15–20 | 149 (12.5) |
21–30 | 473 (39.5) |
31–40 | 388 (32.4) |
41–50 | 128 (10.7) |
≥51 | 58 (4.8) |
Sex (n = 1196) | |
Female | 666 (55.7) |
Male | 530 (44.3) |
Baseline functional status (n = 1047) | |
Working | 651 (62.2) |
Ambulatory | 345 (33.0) |
Bedridden | 51 (4.8) |
Baseline WHO clinical stage (1196) | |
Stage 1 | 61 (5.1) |
Stage 2 | 180 (15.0) |
Stage 3 | 809 (67.7) |
Stage 4 | 146 (12.2) |
First treatment class (n = 1196) | |
AZT-3TC | 732 (61.2) |
D4t-3TC | 36 (3.0) |
D4t (30) | 424 (35.5) |
D4t (40) TDF-ddl |
3 (0.3) 1 (0.08) |
Baseline CD4 count (n = 1196) | |
<200 | 919 (76.8) |
200–349 | 218 (18.2) |
350–499 | 32 (2.7) |
≥500 | 27 (2.3) |
Average CD4 count increment (compared to the baseline)a | |
At 6 month (n = 861) | 228 (60.26) |
At 1 year (n = 787) | 232 (60.66) |
At 2 year (n = 701) | 229 (60.33) |
At 3 year (n = 569) | 264 (63.73) |
At 4 year (n = 378) | 303 (66.87) |
aThe mean estimates were made under the condition of changing denominators because of attritions